Assessment of the impact of disease-modifying therapies on COVID-19 severity in patients with Multiple sclerosis
Latest Information Update: 06 Nov 2020
At a glance
- Drugs Ocrelizumab (Primary) ; Rituximab (Primary) ; Dimethyl fumarate; Natalizumab
- Indications Multiple sclerosis
- Focus Adverse reactions
- 06 Nov 2020 New trial record
- 13 Sep 2020 Results presented at the 8th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis